Cargando…

Correction: Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis — coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829588/ https://www.ncbi.nlm.nih.gov/pubmed/29440167 http://dx.doi.org/10.1136/bmjopen-2017-016617corr1

Ejemplares similares

Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis — coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial
por: Kim, Chi-Hoon, et al.
Publicado: (2017)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Publicado: (2016)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients
por: Park, Seokwoo, et al.
Publicado: (2020)

Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
por: Sudhir, Krishnankutty, et al.
Publicado: (2013)

Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis
por: Luo, Lin, et al.
Publicado: (2022)

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
por: Smits, Pieter C., et al.
Publicado: (2021)

Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials
por: Tsoi, Man-Fung, et al.
Publicado: (2015)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
por: Wada, Tadashi, et al.
Publicado: (2013)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis
por: Khan, Safi U., et al.
Publicado: (2020)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
por: Geng, Xue, et al.
Publicado: (2020)

Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease
por: Krackhardt, Florian, et al.
Publicado: (2020)

Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
por: Yoon, Yong-Hoon, et al.
Publicado: (2022)

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials
por: Lin, Bei-you, et al.
Publicado: (2019)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials
por: Rozemeijer, R., et al.
Publicado: (2018)

Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation
por: Macaione, Francesca, et al.
Publicado: (2012)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease
por: Krackhardt, Florian, et al.
Publicado: (2022)

The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial
por: Park, Kyung Woo, et al.
Publicado: (2012)

Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials
por: Huang, Feng
Publicado: (2018)

Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea—The Effect Trial
por: Cha, Jung-Joon, et al.
Publicado: (2020)

Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing
por: Burlacu, Alexandru, et al.
Publicado: (2020)

Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
por: Cui, Kongyong, et al.
Publicado: (2021)

Short‐term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new‐generation drug‐eluting stent
por: Vranken, Nousjka P. A., et al.
Publicado: (2022)

Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents
por: Brami, Pierre, et al.
Publicado: (2023)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
por: Natsuaki, Masahiro, et al.
Publicado: (2015)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas, Vasileios F, et al.
Publicado: (2015)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

Is the Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents the Longer the Better?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Sirolimus-Eluting Stents vs Uncoated Stents for the Treatment of Proximal Left Anterior Descending Coronary Artery Stenosis
por: Valencia, José, et al.
Publicado: (2007)

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
por: Gragnano, Felice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_opfu90nq36ai7mph0312erdavr